Gossamer Bio Inc (GOSS)

$3.05 -0.03 (-0.97%)
Market Cap 693.51M
Revenue (ttm) 114.70M
Net Income (ttm) -56.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -49.29%
Debt to Equity Ratio 0.00
Volume 5,112,700
Avg Vol 3,781,924
Day's Range N/A - N/A
Shares Out 227.38M
Stochastic %K 44%
Beta 1.95
Analysts Strong Sell
Price Target $9.12

Company Profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercia...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 684 1300
Address:
3115 Merryfield Row, Suite 120, San Diego, United States
Lefthandedchef
Lefthandedchef Sep. 20 at 3:45 AM
$GOSS dip to rip
0 · Reply
boomupwego
boomupwego Sep. 20 at 12:01 AM
$GOSS And…..somebody dumped a portion of those million short shares in the last hour lol good times ahead Monday when they buy them back
0 · Reply
mdalinaqvi
mdalinaqvi Sep. 19 at 9:28 PM
$GOSS sorry was triple witching day today, options related volumes.
0 · Reply
boomupwego
boomupwego Sep. 19 at 8:21 PM
$GOSS Cannot emphasize enough how important it was to close over 2.95 this week. Had two really hard pushes to drop it under 2.90 and both stalled. Consolidation is now confirmed and we should see nothing but up from here. Congrats.
1 · Reply
mdalinaqvi
mdalinaqvi Sep. 19 at 8:12 PM
$GOSS Huge blocks trading even after hours.who is buying?
0 · Reply
mdalinaqvi
mdalinaqvi Sep. 19 at 8:04 PM
$GOSS
0 · Reply
mdalinaqvi
mdalinaqvi Sep. 19 at 8:03 PM
$GOSS Crazy volumes in the dying minutes of trade, bodes well for next week.
0 · Reply
StockScubaDiver
StockScubaDiver Sep. 19 at 7:40 PM
$GOSS 😎
0 · Reply
mmtiddy
mmtiddy Sep. 19 at 4:48 PM
$GOSS Mhmmm… might join you guys
1 · Reply
Finnish_boy
Finnish_boy Sep. 19 at 4:22 PM
$GOSS PH-ILD https://clinicaltrials.gov/study/NCT07181382
1 · Reply
Latest News on GOSS
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 10, 2025, 5:30 PM EDT - 10 days ago

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio: Bullish Ahead Of Seralutinib's Phase 3 Readout

Sep 9, 2025, 9:50 AM EDT - 11 days ago

Gossamer Bio: Bullish Ahead Of Seralutinib's Phase 3 Readout

Gossamer Bio to Present at Upcoming Investor Conferences

Aug 29, 2025, 7:31 AM EDT - 22 days ago

Gossamer Bio to Present at Upcoming Investor Conferences

Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 5, 2025, 4:01 PM EDT - 6 weeks ago

Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH

Jun 16, 2025, 7:31 AM EDT - 3 months ago

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH

Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 9:30 PM EDT - 4 months ago

Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call Transcript

Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

May 15, 2025, 4:01 PM EDT - 4 months ago

Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025

May 12, 2025, 4:01 PM EDT - 4 months ago

Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025

Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference

May 7, 2025, 4:01 PM EDT - 4 months ago

Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Mar 13, 2025, 4:01 PM EDT - 6 months ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD

Feb 13, 2025, 7:42 PM EST - 7 months ago

Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD

Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Feb 3, 2025, 7:01 AM EST - 8 months ago

Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Jan 28, 2025, 7:01 AM EST - 8 months ago

Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 4:03 PM EST - 11 months ago

Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update

Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss

Sep 10, 2024, 1:25 AM EDT - 1 year ago

Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss

Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024

Aug 26, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD ELUT EUDA GDTC GOVX IMRN

Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says

Jun 25, 2024, 2:39 PM EDT - 1 year ago

Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

May 14, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment

May 6, 2024, 7:46 AM EDT - 1 year ago

Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

May 6, 2024, 7:30 AM EDT - 1 year ago

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine

May 3, 2024, 8:02 AM EDT - 1 year ago

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D.

Mar 12, 2024, 7:31 AM EDT - 1 year ago

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D.

Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Mar 5, 2024, 7:31 AM EST - 1 year ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

Dec 13, 2023, 4:01 PM EST - 1 year ago

Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

Dec 5, 2023, 7:01 AM EST - 1 year ago

Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors

Nov 29, 2023, 7:01 AM EST - 1 year ago

Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors

Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update

Nov 9, 2023, 7:31 AM EST - 2 years ago

Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update

Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs

Oct 3, 2023, 4:08 PM EDT - 2 years ago

Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs

Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023

Sep 7, 2023, 7:44 AM EDT - 2 years ago

Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023

Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update

Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results

Jul 24, 2023, 4:16 PM EDT - 2 years ago

Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results

Gossamer Bio Announces $212 Million Private Placement Financing

Jul 20, 2023, 7:56 AM EDT - 2 years ago

Gossamer Bio Announces $212 Million Private Placement Financing

Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference

May 18, 2023, 7:05 AM EDT - 2 years ago

Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference

Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update

May 9, 2023, 4:01 PM EDT - 2 years ago

Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update

Gossamer Bio: Merck's STELLAR Data Impressive, But Game Not Over For Seralutinib

Apr 2, 2023, 4:12 AM EDT - 2 years ago

Gossamer Bio: Merck's STELLAR Data Impressive, But Game Not Over For Seralutinib

Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update

Mar 17, 2023, 7:31 AM EDT - 2 years ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update

Gossamer: Disappointing Phase 2 Results But Too Cheap To Ignore

Jan 30, 2023, 4:48 AM EST - 2 years ago

Gossamer: Disappointing Phase 2 Results But Too Cheap To Ignore

Gossamer Bio: Buying The Savage Dip After A Trial 'Win' May Be Unwise

Dec 8, 2022, 1:27 PM EST - 3 years ago

Gossamer Bio: Buying The Savage Dip After A Trial 'Win' May Be Unwise

Gossamer Bio's stock falls 64% on findings for Phase 2 study for hypertension drug

Dec 6, 2022, 8:19 AM EST - 3 years ago

Gossamer Bio's stock falls 64% on findings for Phase 2 study for hypertension drug

Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH

Dec 6, 2022, 7:15 AM EST - 3 years ago

Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH

Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update

Nov 3, 2022, 4:01 PM EDT - 3 years ago

Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update

This little-known biopharma stock could rally 70%: Goldman Sachs

Oct 20, 2022, 3:35 PM EDT - 3 years ago

This little-known biopharma stock could rally 70%: Goldman Sachs

Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update

Aug 9, 2022, 8:01 AM EDT - 3 years ago

Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update

Gossamer Bio Announces $120 Million Private Placement Financing

Jul 13, 2022, 7:15 AM EDT - 3 years ago

Gossamer Bio Announces $120 Million Private Placement Financing

Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinib's Potential for the Treatment of PAH

Jun 9, 2022, 8:30 AM EDT - 3 years ago

Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinib's Potential for the Treatment of PAH

Lefthandedchef
Lefthandedchef Sep. 20 at 3:45 AM
$GOSS dip to rip
0 · Reply
boomupwego
boomupwego Sep. 20 at 12:01 AM
$GOSS And…..somebody dumped a portion of those million short shares in the last hour lol good times ahead Monday when they buy them back
0 · Reply
mdalinaqvi
mdalinaqvi Sep. 19 at 9:28 PM
$GOSS sorry was triple witching day today, options related volumes.
0 · Reply
boomupwego
boomupwego Sep. 19 at 8:21 PM
$GOSS Cannot emphasize enough how important it was to close over 2.95 this week. Had two really hard pushes to drop it under 2.90 and both stalled. Consolidation is now confirmed and we should see nothing but up from here. Congrats.
1 · Reply
mdalinaqvi
mdalinaqvi Sep. 19 at 8:12 PM
$GOSS Huge blocks trading even after hours.who is buying?
0 · Reply
mdalinaqvi
mdalinaqvi Sep. 19 at 8:04 PM
$GOSS
0 · Reply
mdalinaqvi
mdalinaqvi Sep. 19 at 8:03 PM
$GOSS Crazy volumes in the dying minutes of trade, bodes well for next week.
0 · Reply
StockScubaDiver
StockScubaDiver Sep. 19 at 7:40 PM
$GOSS 😎
0 · Reply
mmtiddy
mmtiddy Sep. 19 at 4:48 PM
$GOSS Mhmmm… might join you guys
1 · Reply
Finnish_boy
Finnish_boy Sep. 19 at 4:22 PM
$GOSS PH-ILD https://clinicaltrials.gov/study/NCT07181382
1 · Reply
wallstpirate
wallstpirate Sep. 19 at 1:43 PM
$HROW $GOSS $NRXS TODAY is international talk like a pirate day. https://en.wikipedia.org/wiki/International_Talk_Like_a_Pirate_Day
1 · Reply
Social_Idiot
Social_Idiot Sep. 19 at 1:15 PM
$GOSS Phase 3 filed: Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) (SERANATA) 24 week trial with 144 week extension to look for emergent AEs. https://clinicaltrials.gov/study/NCT07181382?term=chiesi&rank=1
0 · Reply
ItsAllAboutBeingFirst
ItsAllAboutBeingFirst Sep. 18 at 6:24 PM
$GOSS $LCTX $SANA Lctx baby - technicals are priming hard!
1 · Reply
Invest2live
Invest2live Sep. 18 at 6:16 PM
$GOSS 224% already; congrats 🎈🎉 🎊 Checkout $LPTX and CODX; they are waking up and have long way to go. Also, $SENS and $CUE for longs.
0 · Reply
boomupwego
boomupwego Sep. 18 at 3:56 PM
$GOSS something is brewing. Feel like yesterday was the push to get this under 2.90 but it stalled. Still has a chance of dipping back to the 2.70 range but have a hunch it’s gonna move up. A lot. NFA.
1 · Reply
StockScubaDiver
StockScubaDiver Sep. 18 at 2:30 PM
$GOSS load
0 · Reply
TradingWarriorZ
TradingWarriorZ Sep. 18 at 12:16 PM
$GOSS haven’t jumped in yet. waiting for a drop around 2.7
0 · Reply
Upticksdaily
Upticksdaily Sep. 17 at 5:34 PM
$GOSS just did a top up, sat on my hands waiting for it to break $3 to buy more, will continue to add if we see $2.70
2 · Reply
Finnish_boy
Finnish_boy Sep. 17 at 3:35 PM
$GOSS The image shows a large options trade for Gossamer Bio Inc. ($GOSS) with the following details: Ticker: $GOSS Expiration: January 21, 2028 Type: Call option (C) Strike Price/Price: 3.08 (likely strike or last price) Contracts: 10,000 @ $1.85 each Premium: $1.9M Sentiment: Bullish (B) Sector: Health (HLTH) This indicates a significant bet on $GOSS stock rising above ~$4.85 by 2028.
2 · Reply
ItsAllAboutBeingFirst
ItsAllAboutBeingFirst Sep. 17 at 2:52 PM
$GOSS $LCTX $SANA Lctx wants to go so bad
1 · Reply
TwoToesTrading
TwoToesTrading Sep. 17 at 2:46 PM
$UBER $CIFR $NVDA $AVGO $GOSS
0 · Reply
Hereinbama35
Hereinbama35 Sep. 17 at 2:45 PM
$GOSS All right now, my 65% profits are now becoming 35% profits, gonna have to start skimming soon.
2 · Reply